C60 Fullerene as Synergistic Agent in Tumor-Inhibitory Doxorubicin Treatment

Drugs in R and D

Volumn 14, Issue 4, 2014, Pages 333-340

  Prylutska, Svitlana ^a,b   Grynyuk, Iryna ^a,b   Matyshevska, Olga ^a,b   Prylutskyy, Yuriy ^a,b   Evstigneev, Maxim ^c   Scharff, Peter ^a,d   Ritter, Uwe ^a,d  

^a Joint Ukrainian German Center on Nanobiotechnology   (Ukraine)

^b TARAS SHEVCHENKO NATIONAL UNIVERSITY OF KYIV   (Ukraine)

^c BELGOROD STATE UNIVERSITY   (Russian Federation)

^d ILMENAU UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOXIDANT; C 60 FULLERENE; DOXORUBICIN; FULLERENE DERIVATIVE; GLUTATHIONE PEROXIDASE; NANOPARTICLE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; WATER; COLLOID; FULLERENE C60;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; COLLOID; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; EXPERIMENTAL NEOPLASM; HEART; HISTOPATHOLOGY; HYDRODYNAMICS; IN VIVO STUDY; INFRARED SPECTROSCOPY; LD50; LIGHT SCATTERING; LIVER; LIVER CELL CARCINOMA; MALE; METASTASIS INHIBITION; MOUSE; MOUSE MODEL; NEUTRON SCATTERING; NONHUMAN; SCANNING TUNNELING MICROSCOPY; TUMOR MODEL; TUMOR VOLUME; ULTRAVIOLET SPECTROSCOPY; ADMINISTRATION AND DOSAGE; ANIMAL; CARCINOMA, LEWIS LUNG; CARDIAC MUSCLE; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; METABOLISM; PATHOLOGY;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; CARCINOMA, LEWIS LUNG; COLLOIDS; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FULLERENES; GLUTATHIONE PEROXIDASE; HEART; LIVER; MALE; MICE; MYOCARDIUM; NANOPARTICLES; SUPEROXIDE DISMUTASE;

EID: 84919442443     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-014-0074-4     Document Type: Article

References (40)

1. De Vita VT, Hellman S, Rosenberg SA. Principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1126–61.
2. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, Minotti G. Anthracycline cardiotoxicity. Expert Opin Drug Saf. 2012;11:21–36.
3. 24 against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats with colorectal cancer. Biomaterials. 2009;30:1184–96.
4. 60 fullerenes in anticancer therapy. Cancer Nanotechnol. 2011;2:105–10.
5. 60 fullerenes inhibit the rate of tumor growth and metastasis. Exp Oncol. 2011;33:162–4.
6. Gharbi N, Pressac M, Hadchouel M, Szwarc H, Wilson S, Moussa F. [60] Fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity. Nano Lett. 2005;5:2578–85.
7. Kolosnjaj J, Szwarc H, Moussa F. Toxicity studies of fullerenes and derivatives. Adv Exp Med Biol. 2007;620:168–80.
8. 60 fullerenes in vitro. Fuller Nanotub Carbon Nanostruct. 2008;5–6:698–705.
9. Johnston HJ, Hutchison GR, Christensen FM, Aschberger K, Stone V. The biological mechanisms and physicochemical characteristics responsible for driving fullerene toxicity. Toxicol Sci. 2010;114:162–82.
10. Trpkovic A, Todorovic-Markovic B, Trajkovic V. Toxicity of pristine versus functionalized fullerenes: mechanisms of cell damage and the role of oxidative stress. Arch Toxicol. 2012;86:1809–27.
11. 24 through inhibition of oxidative stress. Pharmacol Rep. 2009;61:335–42.
12. x. Small. 2008;4:1168–75.
13. 24 in doxorubicin-induced hepatotoxicity in rats with mammary carcinomas. Biomaterials. 2008;24–25:3451–60.
14. Perše M, Injac R, Djordjevic A, Štrukelj B. Protective effect of fullerenol on colon cancer development in dimethylhydrazine rat model. Digest J Nanomater Biostruct. 2011;6:1543–51.
15. 60 fullerene on the in vitro action of aromatic drug molecules. Eur Biophys J. 2014;43:265–76.
16. 60 fullerene–doxorubicin complex towards normal and tumor cells in vitro. Biopolym Cell. 2014;30:372–6.
17. Mchedlov-Petrossyan NO. Fullerenes in liquid media: an unsettling intrusion into the solution chemistry. Chem Rev. 2013;113:5149–93.
18. Fan J, Fang G, Zeng F, Wang X, Wu S. Water-dispersible fullerene aggregates as a targeted anticancer prodrug with both chemo- and photodynamic therapeutic actions. Small. 2013;9:613–21.
19. Brant JA, Labille J, Robichaud CO, Wiesner M. Fullerol cluster formation in aqueous solution: implication for environmental release. J Colloid Interface Sci. 2007;314:281–8.
20. Zhao B, He Z, Bilski PJ, Chignell CF. Pristine (C60) and hydroxylated [C60(OH)24] fullerene phototoxicity towards HaCaT keratinocytes: Type I vs Type II mechanisms. Chem Res Toxicol. 2008;21:1056–63.
21. 60 fullerene aqueous colloid solution probed by various techniques. Fuller Nanotub Carbon Nanostruct. 2014;23:530–4.
22. 60 fullerenes in vitro and in a model system. Mol Cryst Liq Cryst. 2007;468:265–74.
23. 60 fullerene solubility in aqueous solution. Langmuir. 2014;30:3967–70.
24. 60 aggregates in solution. Int J Mol Sci. 2011;12:4964–74.
25. 60 fullerene. Mat Wiss Werkst. 2013;44:124–8.
26. 60 disturbs prooxidant–antioxidant balance in leukemic L1210 cells. Mat Wiss Werkst. 2013;44:139–43.
27. Ali SS, Hardt JI, Quick KL, Kim-Han JS, Erlanger BF, Huang TT, Epstein CJ, Dugan LL. A biologically effective fullerene (C60) derivative with superoxide dismutase mimetic properties. Free Radic Biol Med. 2004;37:1191–202.
28. Pani G, Bedogni B, Anzevino R, Colavitti R, Palazzotti B, Borrello S, Galeotti T. Deregulated manganese superoxide dismutase expression and resistance to oxidative injury in p53-deficient cells. Cancer Res. 2000;60:4654–60.
29. Xiong Y, Liu X, Lee CP, Chua BH, Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med. 2006;41:46–55.
30. 60 medium dispersion. J Biochem. 2010;148:289–98.
31. 60 Fullerenes: detection of intracellular photoluminescence and lack of cytotoxic effects. J Nanobiotechnol. 2006;4:14. doi:10.1186/1477-3155-4-14.
32. 60. Bioorg Chem. 1996;24:376–85.
33. 60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex. Biomaterials. 2012;33:2952–60.
34. n nanoparticles: antineoplastic activity of high efficiency and low toxicity. Nano Lett. 2005;5:2050–7.
35. x in mice. J Nanoparticle Res. 2006;8:53–63.
36. Rouse JG, Yang J, Barron AR, Monteiro-Riviere NA. Fullerene-based amino acid nanoparticle interactions with human epidermal keratinocytes. Toxicol In Vitro. 2006;20:1313–20.
37. Murugesan S, Mousa SA, O’Connor LJ, Lincoln DW, Linhardt RJ. Carbon inhibits vascular endothelial growth factor and fibroblast growth factor-promoted angiogenesis. FEBS Lett. 2007;581:1157–60.
38. Meng H, Xing G, Sun B, Zhao F, Lei H, Li W, Song Y, Chen Z, Yuan H, Wang X, Long J, Chen C, Liang X, Zhang N, Chai Z, Zhao Y. Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano. 2010;4:2773–83.
39. Liang XJ, Meng H, Wang Y, He H, Meng J, Lu J, Wang PC, Zhao Y, Gao X, Sun B, Chen C, Xing G, Shen D, Gottesman MM, Wu Y, Yin JJ, Jia L. Metallofullerene nanoparticles circumvent tumor resistance to cisplatin by reactivating endocytosis. Proc Natl Acad Sci USA. 2010;107:7449–54.
40. Li YY, Tian YH, Nie GJ. Antineoplastic activities of Gd@C82(OH)22 nanoparticles: tumor microenvironment regulation. Life Sci. 2012;55:884–90.